Selective estrogen-receptor (ER) modulators (SERMs) are synthetic nonsteroidal compounds that switch on and switch off target sites throughout the body. Tamoxifen, the pioneering SERM, blocks estrogen ...

Do SERMs Favorably Impact Clinical Markers of Cardiovascular Risk? In women, menopause is accompanied by clear changes in serum lipoproteins, [30] and plasma lipoprotein levels are clear predictors of ...

S-Phase Fraction and Urokinase Plasminogen Activator Are Better Markers for Distant Recurrences Than Nottingham Prognostic Index and Histologic Grade in a Prospective Study of Premenopausal Lymph Node ...

A research paper published today (8 February 2024) in The Lancet Oncology demonstrates that the drug enobosarm, a selective androgen receptor modulator which stimulates the male sex hormone receptor ...

Athira Pharma has joined an attempt to rescue an asset abandoned by Pfizer. The biotech has secured near-global rights to a phase 3 breast cancer prospect in a deal with Sermonix Pharmaceuticals.

Hormone therapy in older women with breast cancer was associated with a reduced risk of subsequent dementia, a retrospective study of Medicare patients suggested. Breast cancer patients who received ...

Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as ...

Athira Pharma Inc (NASDAQ:ATHA) shares soared 73.4% in premarket trading on Thursday after the clinical-stage ...

Investing.com -- Athira Pharma Inc (NASDAQ:ATHA) stock surged 73.4% in premarket trading Thursday after the clinical-stage biopharmaceutical company announced it has acquired global rights to develop ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, ...